GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (FRA:B9A) » Definitions » Debt-to-Revenue

BioArctic AB (FRA:B9A) Debt-to-Revenue : 0.18 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioArctic AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BioArctic AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.13 Mil. BioArctic AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €3.84 Mil. BioArctic AB's annualized Revenue for the quarter that ended in Sep. 2024 was €27.00 Mil. BioArctic AB's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.18.


BioArctic AB Debt-to-Revenue Historical Data

The historical data trend for BioArctic AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Debt-to-Revenue Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.10 0.33 0.69 0.04 0.01

BioArctic AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.11 0.04 0.30 0.18

Competitive Comparison of BioArctic AB's Debt-to-Revenue

For the Biotechnology subindustry, BioArctic AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioArctic AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Debt-to-Revenue falls into.



BioArctic AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BioArctic AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.253 + 0.192) / 55.068
=0.01

BioArctic AB's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.13 + 3.835) / 27
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


BioArctic AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB Business Description

Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB Headlines

No Headlines